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Abstract
We have recently reported that selective cannabinoid 2 (CB2) receptor agonists upregulate 5-HT2A
receptors by enhancing ERK1/2 signaling in prefrontal cortex (PFCx). Increased activity of
cortical 5-HT2A receptors has been associated with several neuropsychiatric disorders such as
anxiety and schizophrenia. Here we examine the mechanisms involved in this enhanced ERK1/2
activation in rat PFCx and in a neuronal cell model. Sprague-Dawley rats treated with a non-
selective cannabinoid agonist (CP55940, 50 μg/kg, 7 days, i.p.) showed enhanced co-
immunoprecipitation of β-Arrestin 2 and ERK1/2, enhanced pERK protein levels, and enhanced
expression of β-Arrestin 2 mRNA and protein levels in PFCx. In a neuronal cell line, we found
that selective CB2 receptor agonists upregulate β-Arrestin 2, an effect that was prevented by
selective CB2 receptor antagonist JTE-907 and CB2 shRNA lentiviral particles. Additionally,
inhibition of clathrin-mediated endocytosis, ERK1/2, and the AP-1 transcription factor also
prevented the cannabinoid receptor-induced upregulation of β-Arrestin 2. Our results suggest that
sustained activation of CB2 receptors would enhance β-Arrestin 2 expression possibly
contributing to its increased interaction with ERK1/2 thereby driving the upregulation of 5-HT2A
receptors. The CB2 receptor-mediated upregulation of β-Arrestin 2 would be mediated, at least in
part, by an ERK1/2-dependent activation of AP-1. These data could provide the rationale for some
of the adverse effects associated with repeated cannabinoid exposure and shed light on some CB2
receptor agonists that could represent an alternative therapeutic because of their minimal effect on
serotonergic neurotransmission.
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Cannabinoid receptor agonists are being shown to have wide therapeutic applications in the
treatment of conditions such as stroke, neuropathic pain, neurodegenerative diseases, and
cocaine addiction [1–4]. However, recent and independent clinical studies provide strong
evidence indicating that sustained use of nonselective cannabinoid agonists may precipitate
the onset of mental disorders associated with dysfunction of serotonin 2A (5-HT2A) receptor
neurotransmission in prefrontal cortex (PFCx), such as schizophrenia, psychosis and anxiety
[5–8]. Although the precise mechanism by which repeated cannabinoid exposure may
precipitate these disorders is unknown, we have recently provided evidence that cannabinoid
agonists induce a strong upregulation and increase activity of 5-HT2A receptors in vivo and
in vitro [9;10].
Cannabinoid agonists can produce their physiological effects through the activation of two
G-protein coupled cannabinoid receptors in the brain, CB1 and CB2 receptors [11;12]. CB1
and CB2 receptors bind endocannabinoids, synthetic cannabinoids, and cannabinoids found
in nature (such as Cannabis sativa) with high affinity [11;12]. Although only CB1 receptors
were initially identified in the brain [13], later studies have identified CB2 receptors in
several brain areas such as PFCx, hippocampus, amygdala, substantia nigra, and cerebellum
[14;15], triggering a reevaluation of the possible roles that CB2 receptors may play in the
brain. These cannabinoid receptors couple to Gi/o class of G-proteins and can activate
ERK1/2 signaling in a either G-protein or β-Arrestin dependent pathway [12;16]. While G-
protein-mediated activation of ERK1/2 is transient and peaks within 2–5 minutes [17;18], β-
Arrestins can form a scaffolding complex with Raf-1, MEK, and ERK1/2 which can regulate
the long-term activation of ERK1/2 after β-Arrestin mediated internalization of the G-
protein coupled receptor or GPCR [17–19].
We recently reported that 5-HT2A receptors are upregulated by repeated exposures to
cannabinoid agonists through a mechanism that would involve CB2 receptor-mediated
activation of ERK1/2 signaling, and that is independent of CB1 receptor activation [9;10].
Moreover, we presented experimental evidence that sustained treatment with a non-selective
cannabinoid agonist (CP55940) or selective CB2 receptor agonists (JWH-133 or GP1a)
upregulate 5-HT2A receptors in a neuronal cell line [10], an effect that was not replicated by
selective CB1 agonists [10]. The CB2 receptor is a class A GPCR which means it would
preferentially interact with β-Arrestin 2 to form a scaffolding complex with ERK1/2 [20].
Accordingly, we also reported that the cannabinoid receptor agonist-induced upregulation
of 5-HT2A receptors was prevented in cells stably transfected with either CB2 or β-Arrestin
2 shRNA lentiviral particles [10].
Here we examined mechanisms which could contribute to the CB2 receptor- and ERK1/2-
mediated enhanced activation of 5-HT2A receptors. We studied the involvement of selective
CB1 and CB2 receptor agonists on the regulation of β-Arrestin 2 expression and the
formation of a β-Arrestin 2 and ERK1/2 protein complex. Our results indicate that repeated
exposure to cannabinoids enhance the protein interaction between β-Arrestin 2 and ERK1/2.
Furthermore, cannabinoid agonists upregulated β-Arrestin 2 by a mechanism that would
require internalization of CB2 receptors, activation of ERK1/2, and activation of the
transcription factor AP-1. We also detected a strong CB2, but not CB1, receptor activation
upregulation of β-Arrestin 2 in a neuronal cell line. We hypothesize that the data presented
here could provide, at least in part, a molecular mechanism by which repeated exposure to
cannabinoids might be relevant to some cognitive and mood disorders by upregulating and
enhancing the activity of 5-HT2A receptors.
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2. Materials and Methods
2.1 Drugs
(−)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-
hydroxypropyl)cyclohexanol (CP55940), a CB1 and CB2 receptor agonist; (6aR,10aR)-3-
(1,1-Dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
(JWH-133) a selective CB2 agonist; N-(Piperidin-1-yl)-1-(2,4-dichlorophenyl)-1,4-
dihydro-6-methylindeno[1,2-c]pyrazole-3-carboxamide (GP1a) a highly selective CB2
receptor agonist; N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA) a highly
selective CB1 receptor agonist; 2-(2-Chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-
difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a
selective CB1 receptor antagonist; N-(1,3-Benzodioxol-5-ylmethyl)-1,2-dihydro-7-
methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide (JTE-907) a selective CB2 receptor
antagonist/inverse agonist; N-(Cyclopropylmethoxy)-3,4,5-trifluoro-2-[(4-iodo-2-
methylphenyl)amino]-benzamide (PD198306) a potent and selective ERK1/2 inhibitor; and
(E,E,Z,E)-3-Methyl-7-(4-methylphenyl)-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-
nonatetraenoic acid (SR11302), an inhibitor of activating protein-1 transcription factor
activity were purchased from Tocris (Ellisville, MO). Naphthol AS-E phosphate, a CREB
inhibitor, was purchased from Sigma-Aldrich Inc. (St. Louis, MO). Naphthalen-1-yl-(1-
butylindol-3-yl)methanone (JWH-073), a CB1/CB2 receptor agonist, was synthesized in the
laboratory of Dr. Thomas Prisinzano as described previously [21].
2.2 Animal Experimental Protocol
Male Sprague-Dawley rats (225–275 g; Harlan Laboratories, Indianapolis, IN) were housed
two per cage in a temperature-, humidity-, and light-controlled room (12 hr light/dark cycle,
lights on 7:00 AM–7:00 PM). Food and water were available ad libitum. All procedures
were conducted in accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals as approved by the University of Kansas Institutional Animal
Care and Use Committee (IACUC).
After arrival, the rats were allowed to acclimate to their environment for at least 4 days prior
to the start of the treatment period. Eight rats were randomly assigned to each group, cage
mates were assigned to the same treatment group. The body weight of each rat was recorded
every other day. All solutions were made fresh before administration and rats were injected
with either vehicle (Tween-80/ethanol/saline (1:1:18); 1mL/kg, i.p.) or CP55940 (0.05 mg/
kg, i.p.) once a day for 7 days. Rats were sacrificed by decapitation 48 h after the last
CP55940 injection. The dose and time course for CP55940 were chosen based upon the
literature that reported that similar doses induced increased anxiety-like behaviors [22;23]
and upregulation of 5-HT2A receptors in rat PFCx [9]. In our preliminary experiments we
also noticed that doses higher than 0.2 mg/kg prevent weight gain in rats after 2 days of
CP55940 exposure. After sacrifice, brains were immediately removed and PFCx was
dissected and frozen in dry ice.
2.3 Co-Immunoprecipitation
Co-immunoprecipitation (co-IP) was conducted with the Thermo Scientific Pierce co-IP kit
following manufacturer’s protocol and as previously described [9]. The β-Arrestin 2 and
ERK1/2 antibody was purchased from Santa Cruz, CA. Briefly, β-Arrestin 2 antibody was
incubated with AminoLink Plus coupling resin for 2 hrs. This resin was incubated with pre-
cleared PFCx lysate (300 μg) from either vehicle or CP55940 treated rats overnight. A
negative control included a non-reactive resin that was incubated with β-Arrestin 2 antibody
for 2 hrs and then pre-cleared PFCx lysate from either CP55940 or vehicle-treated rats
overnight. After the overnight incubation, the resins were washed (3x) and the protein eluted
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using elution buffer. Samples were analyzed by Western blot using ERK1/2 antibody. The
specificity of the β-Arrestin 2 or ERK1/2 antibody has been verified in the literature
[10;24;25].
2.4 Western Blot
Membrane-associated fractions were isolated using the ProteoExtract™ Native Membrane
Protein Extraction kit (Calbiochem, La Jolla, CA) and Nuclear-associated fractions were
isolated using NE-PER ® Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific,
IL). Expression of β-Arrestin 2, pERK, and ERK1/2 were determined by western blot
analysis as previous described [26]. pERK antibody was purchased from Santa Cruz, CA.
The specificity of the antibody has been verified in the literature [27]. Protein loading for
each lane was verified using an anti-actin antibody (Santa Cruz Biotechnology, Inc.).
Negative controls included either the omission of primary antibody or addition of
preimmune rabbit immunoglobulins. Films were analyzed densitometrically with values
calculated from the integrated optical density (IOD) of each band using Scion Image
software (Scion Corporation, Frederick, MD, USA), as previously described [26;28]. All
samples were standardized to controls and normalized to their respective actin levels.
2.5 CP55940-induced ERK1/2 activation in PFCx tissue
This assay was based upon a PLCβ assay that has been previously described [26]. PFCx
tissue from vehicle or CP55940 treated rats was homogenized in homogenization buffer (1
mL/0.1 g of tissue) with protease inhibitor for 3 seconds. Samples were vortexed and
centrifuged at 13,000 rpm at 4°C for 10 minutes. The supernatant was removed, 500 μL of
homogenate buffer was added to the pellet, sampes were vortexed and centrifuged at 13,000
rpm at 4°C for 10 minutes. This wash process was repeated three times. Protein levels were
measured and equalized. Vehicle and CP55940 samples were treated with 1 nM CP55940
and incubated for 15 minutes. Western blot analysis was utilized to measure pERK levels as
previously described above.
2.6 Quantitative Real-Time PCR
These reactions were prepared using QuantiFast SYBR Green PCR Kit (Qiagen, Valencia,
CA) and the ABI 7500 fast real time PCR system (Applied Biosystems, Foster City, CA)
and then data was analyzed using the comparative cycle threshold (Ct) method as previously
described [9]. The primers used in this manuscript were: 5-HT2A (F:5′-
AACGGTCCATCCACAGAG-3′ and R:5′-AACAGGAAGAACACGATGC-3′), β-
Arrestin 2 (F:5′-AGCACCGCGCAGTACAAGT-3′, 5′-R:CACGCTTCTCTCGGTTGTCA
-3′) and GAPDH (F: 5′-TGGAGTCTACTGGCGTCTTCAC-3′ and R:5′-
GGCATGGACTGTGGTCATGA-3′). These primers have been previously validated in the
literature [9;10;29;30].
2.7 Cell Culture Protocol
CLU213 cells, a rat neuronal cell line that co-expresses 5-HT2A, D2, CB1 and CB2
receptors, were purchased from Cedarlane Laboratories (Burlington, NC). CLU213 were
grown on 100-mm2 plates treated with polystyrene (Corning Incorporated, Corning, NY)
and maintained in 5% CO2 at 37°C, in Dulbecco’s modified eagle medium (DMEM;
Mediatech Inc, Manassas, VA) containing 10% fetal bovine serum (FBS; Thermo Scientific,
Logan, UT).
2.7.1 Effect of Non-Selective and Selective CB1 and CB2 Receptor Agonists on
β-Arrestin 2 mRNA and protein levels—CLU213 cells were incubated with either
vehicle (ethanol 0.01% final concentration), CP55940 1 nM (CB1 and CB2 agonist, Ki: 0.58
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nM and 0.68 nM for CB1 and CB2 receptors, respectively) [31]; JWH-133 30 nM (selective
CB2 agonist, Ki: 3.4 nM and 677 nM for CB2 and CB1 receptors, respectively) [32], GP1a 1
nM (highly selective CB2 agonist, Ki: 0.037 nM and 353 nM for CB2 and CB1 receptors,
respectively) [33], ACEA 15 nM (selective CB1 agonist, Ki: 1.4 nM and 3.1 μM for CB1
and CB2 receptors, respectively) [34] or JWH-073 40 nM (CB1 and CB2 agonist, Ki: 8.9
nM and 38 nM for CB1 and CB2 receptors, respectively) [21;35] for 24 hours. mRNA was
isolated and qRT-PCR for β-Arrestin 2 mRNA were performed as described above.
In a separate experiment, cells were treated with vehicle (ethanol 0.01% final concentration),
CP55940 (1 nM), JWH-133 (30 nM) or GP1a (1 nM) for 72 hours. Cells were washed (3x)
with PBS every 24 hours and fresh vehicle, CP55940, JWH-133 or GP1a were added.
Expression of membrane-associated β-Arrestin 2 was determined by Western blot as
previously described.
2.7.2 Effect of selective cannabinoid receptor antagonists on the CP55940-
induced upregulation of β-Arrestin 2—CLU213 cells were pretreated with either
vehicle (ethanol 0.01% final concentration); PF-514273 20 nM (CB1 antagonist, Ki: 1 nM
and >10,000 nM for CB1 and CB2 receptor, respectively) [36]; or JTE-907 10 nM (CB2
antagonist, Ki: 0.38 and 1,050 nM for CB2 and CB1 receptors, respectively) [37]. Twenty
minutes later cells were incubated with either vehicle (ethanol 0.01% final concentration) or
CP55940 1 nM for 24 hours. mRNA was isolated and qRT-PCR for β-Arrestin 2 mRNA
was performed.
2.7.3 Effect of selective CB2 receptor antagonist on GP1a-induced
upregulation of β-Arrestin 2—CLU213 cells were pretreated with either vehicle
(ethanol 0.01% final concentration) or JTE-907 (10 nM, a CB2 receptor antagonist) [37].
Twenty min later cells were incubated with either vehicle (ethanol 0.01% final
concentration) or GP1a (1nM) for 24 hours. mRNA was isolated and qRT-PCR for β-
Arrestin 2 mRNA was determined.
2.7.4 Lentivirus and stable transduction of shRNAs in CLU213 cells—β-Arrestin
2 shRNA (r), CB2 shRNA (r), CB1 shRNA (r), copGFP control, control shRNA lentiviral
particles, polybrene, and puromyocin were purchased from Santa Cruz, CA. Optimal
transduction conditions were elucidated utilizing copGFP control lentiviral particles prior to
transduction with β-Arrestin 2 shRNA or CB2 shRNA lentiviral particles and then
transduction was conducted as previously described [10]. Cells were analyzed for β-Arrestin
2, CB2, or CB1 knockdown one week after initiation of puromyocin selection.
2.7.5 Effect of CB2 or CB1 shRNA lentivirus transfection on cannabinoid-
induced upregulation of β-Arrestin 2—After confirming that treatment with the CB2
or CB1 shRNA lentivirus reduced CB2 or CB1 mRNA 80% and 70%, respectively, control,
CB2, or CB1 shRNA treated cells were treated with either vehicle (ethanol 0.01% final
concentration), CP55940 1 nM, JWH-133 30 nM, or GP1a 1 nM for 24 hours. mRNA was
isolated from cells and qRT PCR was performed for β-Arrestin 2 mRNA levels as
previously described above.
2.7.6 Effect of Concanavalin A (ConA) treatment on cannabinoid-induced
increases in β-Arrestin 2 mRNA—Cells were pretreated with either vehicle or 250 μg/
mL ConA for 20 minutes [10;38]. Twenty minutes later cells were incubated with either
vehicle (ethanol 0.01% final concentration), CP55940 (1 nM), or GP1a (1 nM). mRNA was
isolated and qRT-PCR was performed for β-Arrestin 2 mRNA levels.
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2.7.7 Effect of a selective ERK1/2 inhibitor on GP1a-Induced Increases in β-
Arrestin 2 mRNA—CLU213 cells were treated with either vehicle (ethanol 0.01% final
concentration) or PD198306 (200 nM) [10]. Twenty minutes later cells were incubated with
either vehicle (ethanol 0.01% final concentration) or GP1a (1 nM). mRNA was isolated and
qRT-PCR was used to measure β-Arrestin 2 mRNA levels.
2.7.8 Effect of β-Arrestin 2 shRNA lentivirus transfection on cannabinoid-
induced ERK1/2 activation—After confirming that treatment with the β-Arrestin 2
lentivirus particles reduced β-Arrestin 2 mRNA and protein levels 85%, control or β-
Arrestin 2 treated cells were treated with either vehicle (ethanol 0.01% final concentration),
CP55940 1 nM or GP1a 1 nM for 15 minutes. Nuclear fractions were isolated and western
blot analysis was utilized to measure nuclear-associated pERK levels.
2.7.9 Effect of Transcription Factor Inhibitors on GP1a-Induced Upregulation
of β-Arrestin 2 mRNA—CLU213 cells were treated with either vehicle (ethanol 0.01%),
Naphthol AS-E phosphate (10 μM) [39] or SR11302 (1 μM) [40] for 20 minutes. Cells were
then treated with either vehicle (ethanol 0.01%) or GP1a (1 nM) for 24 hours. mRNA was
isolated and qRT-PCR for β-Arrestin 2 mRNA was performed as previously described.
2.7.10 Effect of β-Arrestin 2 shRNA lentivirus treatment on GP1a-induced
upregulation of 5-HT2A mRNA—Control or β-Arrestin 2 shRNA lentivirus treated cells
were treated with either vehicle (ethanol 0.01% final concentration), GP1a 1 nM, ACEA 15
nM or JWH-073 40 nM for 24 hours. mRNA was isolated and qRT-PCR for β-Arrestin 2
mRNA was performed.
2.8 Statistics
All data are expressed as the mean ± S.E.M., where n indicates the number of rats or cell
culture plates per group. Data was analyzed by an unpaired Student’s t-test or ANOVA
(Newman-Keuls post-hoc test). GB-STAT software (Dynamic Microsystems, Inc., Silver
Spring, MD, USA) was used for all statistical analyses.
3. Results
3.1 Chronic CP55940 treatment induces enhanced β-Arrestin 2 and ERK1/2 interaction in
PFCx
Our previous work has shown that some cannabinoid agonists can enhance 5-HT2A receptor
expression by means of a mechanism that involves CB2 receptor regulation of ERK1/2
activation. [9;10]. Cannabinoid receptors could produce a long-term ERK1/2 activation by a
mechanism that may involve a β-Arrestin-ERK1/2 scaffolding complex [17–19].
Specifically, CB2 receptors that are a class A GPCR would preferentially interact with β-
Arrestin 2, which may facilitate and enhance the interaction between β-Arrestin and ERK1/2
resulting in long-term ERK1/2 activation [20]. Here, we used co-immunoprecipitation
protocols to study the effect of CP55940 treatment on the physical interaction between β-
Arrestin 2 and ERK1/2 in rat PFCx (Fig. 1. A). We used β-Arrestin 2 antibody as bait and
ERK1/2 antibody as prey. Inactive columns which are unable to bind β-Arrestin 2 antibody
were used as a control as described in methods. We found that ERK1/2 co-precipitates with
β-Arrestin 2 when we used β-Arrestin 2 as bait (Fig. 1. A, lanes 3 & 4). Interestingly, we
detected a significant (p<0.05) two-fold increase in the interaction between β-Arrestin 2 and
ERK1/2 in PFCx of CP55940-treated rats compared to vehicle treated controls (Fig. 1. A,
lane 3 and 4, vehicle- and CP55940-treated animals, respectively). No co-precipitation of β-
Arrestin 2 and ERK1/2 was detected using the inactive columns (Fig. 1. A, lanes 5 & 6).
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3.2 Chronic CP55940 treatment enhances ERK1/2 activation in PFCx homogenates after an
acute challenge with CP55940
The increased interaction between β-Arrestin 2 and ERK1/2 proteins could lead to an
enhanced ERK1/2 signaling pathway activity. We then designed an in vitro experiment to
measure acute CP55940-induced ERK phosphorylation in PFCx homogenates of vehicle
and CP55940-treated rats. ERK activation (phosphorylation) was induced by a short
(15min) incubation of the homogenates with 1nM CP55940. We found that this CP55940
challenge induced a significantly (p<0.01) greater ERK1/2 phosphorylation in PFCx
homogenates of CP55940 treated rats compared to vehicle controls (78 ± 5% increase in
CP55940 compared to controls, Fig. 1. B). No significant differences (p>0.05) in total
ERK1/2 protein levels were detected between both experimental groups.
3.3 Chronic CP55940 treatment upregulates β-Arrestin 2 expression but not ERK1/2 in rat
PFCx
We also studied the effect of repeated exposure of CP55940 on β-Arrestin 2 and ERK1/2
protein expression in rat PFCx since changes in the levels of these proteins could explain the
enhanced: (1) β-Arrestin 2 and ERK1/2 interaction (Fig. 1.A); and (2) ERK1/2 signaling
pathway (Fig. 1.B) in PFCx of CP55940-treated rats compared to vehicle controls. Here, we
examined the effect of repeated CP55940 (50μg/kg for 7 days) exposure on the expression
of membrane-associated β-Arrestin 2 and total ERK1/2 protein levels in rat PFCx.
CP55940 treatment produced a significant (p<0.01) increase in β-Arrestin 2 membrane-
associated protein levels compared to vehicle treated controls (108 ± 13% increase
compared to controls, Fig. 1.C). Interestingly, CP55940 treatment did not significantly alter
(p>0.05) total ERK1/2 protein levels in rat PFCx (Fig. 1.D). Actin was used as a protein
loading controls in the Western blots as described in methods. Cannabinoid-induced
upregulation of β-Arrestin 2 mRNA synthesis could contribute to the changes in membrane-
associated β-Arrestin 2 protein levels so we also determined the effect of CP55940
treatment on β-Arrestin 2 mRNA levels. β-Arrestin 2 mRNA was significantly (p<0.05)
increased (two-fold) in PFCx of CP55940-treated rats compared to vehicle-treated controls
(107 ± 15% increase compared to controls, Fig. 1.E).
3.4 β-Arrestin 2 is involved in the cannabinoid-induced upregulation of 5-HT2A receptors
We used neuronal cells stably transfected with either β-Arrestin 2 or control shRNA
lentiviral particles to study the contribution of β-Arrestin 2 on the cannabinoid-induced
upregulation of 5-HT2A receptors. We have previous shown that GP1a (a selective CB2
receptor agonist) upregulates 5-HT2A receptors while treatment with ACEA (a selective
CB1 receptor agonist) does not significantly alter 5-HT2A receptor mRNA levels [9].
Treatment with β-Arrestin 2 shRNA lentiviral particles significantly (p<0.01) reduced β-
Arrestin 2 mRNA and protein levels by approximately 85% [10]. Here, cells were treated
with either vehicle, GP1a (1 nM), or ACEA (15 nM) for 24 hours. We found that GP1a
upregulated 5-HT2A mRNA in control shRNA treated cells by 109 ± 2% (Fig. 1.F). ACEA
did not significantly modify 5-HT2A receptor mRNA levels in control shRNA treated cells
compared to vehicle treated controls. Noteworthy, the GP1a-induced upregulation of 5-
HT2A mRNA levels was significantly (p<0.05) reduced in cells stably transfected with β-
Arrestin 2 shRNA lentiviral particles. GP1a-mediated increases in 5-HT2A mRNA levels
was prevented in β-Arrestin 2 shRNA treated cells (Fig. 1.F). The two-way ANOVA
showed main effects of transfection (F1,63.37 =0.39, p<0.0001), CB2 agonist (F3,71.59 =0.44,
p<0.0001), and a main interaction between these two factors (F3,61.22 =0.38, p<0.0001) on
5-HT2A mRNA levels. In summary, these data suggest that CP55940 treatment might
heighten the β-Arrestin 2 and ERK1/2 interaction that would enhance ERK1/2 signaling in
rat PFCx through upregulation of β-Arrestin 2. This later protein is necessary for the
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cannabinoid-induced upregulation of 5-HT2A receptors as indicated in studies conducted in
our neuronal cell model.
3.5 CP55940 and selective CB2 receptor agonists, JWH-133 and GP1a, upregulate β-
Arrestin 2 in CLU213 cells
Next, we used a neuronal cell culture model to elucidate the mechanisms underlying
cannabinoid-induced upregulation of β-Arrestin 2. Here, cells were incubated with either
vehicle, CP55940 (CB1/CB2 receptor agonist, 1nM), selective CB2 receptor agonists
JWH-133 (30nM) or GP1a (1nM), or a selective CB1 agonist ACEA (15nM) for 24 hours.
We found that sustained CP55940 exposure significantly (p<0.01) increased β-Arrestin 2
mRNA levels compared to vehicle treated cells (67 ± 5% increase, Fig. 2.A). Noteworthy,
sustained treatment with either JWH-133 or GP1a, but not ACEA, significantly increased
(p<0.01) β-Arrestin 2 mRNA levels (72 ± 5% and 64 ± 4% increase compared to controls,
respectively)(Fig. 2.A). We also determined what effect CP55940, JWH-133, and GP1a
treatment had on β-Arrestin 2 protein levels. We found that treatment with CP55940 (1nM),
JWH-133 (30nM), and GP1a (1nM) also significantly increased (p<0.01) β-Arrestin 2
protein levels compared to vehicle treated controls (105 ± 26%, 120 ± 12%, and 143 ± 21%
increase compared to vehicle controls, respectively)(Fig. 2B).
3.6 A selective CB2 receptor antagonist, JTE-907, prevents CP55940- and the GP1a-
induced increases in β-Arrestin 2 mRNA levels
The evidence presented above suggested that the cannabinoid-induced upregulation of β-
Arrestin 2 might be mediated by the CB2 receptors. In order to examine the relative roles of
CB1 and CB2 receptors in the upregulation of β-Arrestin 2, cells were pretreated with either
vehicle, a selective CB1 receptor antagonist PF-514273 (20nM), or a selective CB2 receptor
antagonist JTE-907 (10nM) and then treated with either vehicle or CP55940 (1nM) for 24
hours. CP55940 treatment significantly (p<0.01) increased β-Arrestin 2 mRNA levels
compared to vehicle treated controls (75 ± 2% increase compared to controls, Fig. 2.C). We
found that PF-514273 pretreatment did not inhibit or significantly (p>0.05) modify the
CP55940-induced increases in β-Arrestin 2 mRNA levels. Noteworthy, pretreatment with a
selective CB2 receptor antagonist, JTE-907, prevented the CP55940-induced increases in β-
Arrestin 2 mRNA levels (p<0.01, Fig. 2.C). No significant (p>0.05) effect of PF-514273 or
JTE-907 pretreatment was found on basal β-Arrestin 2 mRNA levels. The two-way
ANOVA showed main effects of cannabinoid antagonists (F2,37.3 =0.28, p<0.0001),
cannabinoid agonists (F1,143.3 =1.08, p<0.0001), and a main interaction between these two
factors (F2,36.9 =0.28, p<0.0001) on β-Arrestin 2 mRNA levels.
In order to more thoroughly investigate the role of CB2 receptors in the cannabinoid-induced
upregulation of β-Arrestin 2 mRNA levels, we pretreated cells with the either vehicle or
selective CB2 antagonist JTE-907 and then treated cells with vehicle or a highly selective
CB2 receptor agonist GP1a. As expected, GP1a treatment significantly (p<0.01) increased
β-Arrestin 2 mRNA levels (74 ± 5% increase compared to controls, Fig. 2.D). This GP1a-
induced upregulation of β-Arrestin 2 was prevented (p<0.01) in cells pretreated with
JTE-907 (Fig. 2.D). The two-way ANOVA showed main effects of JTE-907 pretreatment
(F1,35.4 =0.28, p<0.0003), GP1a treatment (F1,68.3 = 0.54, p<0.0001), and a main interaction
between these two factors (F1,37.1 =0.29, p<0.0003) on β-Arrestin 2 mRNA levels.
3.7 CB2, but not CB1, shRNA lentiviral particle treatment prevents cannabinoid-induced
increases in β-Arrestin 2 mRNA level
We also used cells stably transfected with control, CB2, or CB1 shRNA lentiviral particles
to study whether the effect of cannabinoid agonists on β-Arrestin 2 mRNA levels. CB1 and
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CB2 mRNA levels were significantly reduced by approximately 75–80% in neuronal cells
treated with either CB1 or CB2 shRNA lentiviral particles, respectively (Fig. 3.A). We have
previously reported similar reductions (75–80%) in protein levels of these receptors after
transfection with these shRNA lentiviral particles [10].
Control or CB2 shRNA lentiviral transfected cells were treated with either vehicle, CP55940
(1nM), JWH-133 (30nM) or GP1a (1nM). We found that treatment with CP55940,
JWH-133, or GP1a significantly (p<0.01) increased β-Arrestin 2 mRNA levels in control
shRNA treated cells compared to vehicle-treated controls (76 ± 3%, 65 ± 2%, and 72 ± 5%
increase, respectively)(Fig 3B). Noteworthy, CB2 shRNA treatment prevented (p<0.01) the
CP55940, JWH-133, and GP1a induced increases in β-Arrestin 2 mRNA levels. CB2
shRNA lentivirus treatment did not significantly (p>0.01) alter basal β-Arrestin 2 mRNA
levels. The two-way ANOVA for β-Arrestin 2 mRNA showed significant main effects of
transfection (F3,97.9 = 0.83, p<0.001) and cannabinoid agonist treatment (F1,33.2 =0.28,
p<0.0001). There was a significant interaction between transfection and cannabinoid agonist
treatment (F3,23.1 =0.19, p<0.0001).
We also determined what effect CP55940, JWH-133 and GP1a treatment had on β-Arrestin
2 upregulation in control or CB1 shRNA lentivirus transfected cells. In control shRNA
treated cells, CP55940, JWH-133, and GP1a treatment significantly (p<0.01) increased β-
Arrestin 2 mRNA levels compared to vehicle treated controls (68 ± 3%, 74 ± 5%, and 71 ±
5% increase, respectively)(Fig. 3.C). Noteworthy, treatment with CB1 shRNA lentiviral
particles did not prevent or significantly modify the CP55940, JWH-133, or GP1a-induced
increases in β-Arrestin 2 mRNA levels compared to control shRNA treated cells (Fig. 3. C).
The two-way ANOVA for β-Arrestin 2 mRNA showed significant main effects of
transfection (F1,7.05 = 0.03, p<0.0173) and cannabinoid agonist treatment (F3,180.67 =0.75,
p<0.0001). There was no significant interaction between transfection and cannabinoid
agonist treatment (F3,0.11=0.0005, p>0.9526). This evidence indicates that CB2, but not
CB1, receptors, would mediate the cannabinoid-induced upregulation of β-Arrestin 2.
3.8 Effect of cannabinoid receptor internalization on the CB2-mediated upregulation of β-
Arrestin 2 mRNA
Next, we investigated whether CB2 receptor internalization may be involved in the
cannabinoid-induced upregulation of β-Arrestin 2. Internalization of membrane-associated
receptors could be a very important step in the signaling of CB2 receptors [41]. Specifically,
CB2-induced ERK1/2 activation may require the internalization of membrane-associated
CB2 receptors [41]. Here, we used two different approaches to study the role of
internalization of CB2 receptors on β-Arrestin 2 upregulation: (1) ConA treatment to prevent
CB2 receptor internalization [10]; and (2) different cannabinoid agonists that are either good
or poor internalizers of CB2 receptors [41].
Currently, there are several protocols that are commonly used to prevent clathrin-mediated
internalization of GPCR which include: ConA, hypertonic sucrose, or depletion of
intercellular potassium [38]. Here we pretreated cells with vehicle or ConA and then treated
cells with either vehicle, CP55940 (1nM) or GP1a (1nM) for 24h. Our previous studies
suggested that this ConA pretreatment decreased the cannabinoid-induced translocation of
CB2 receptors from the membrane to the cytosol and prevented the cannabinoid-induced
ERK1/2 activation [10]. CP55940 and GP1a significantly (p<0.01) increased β-Arrestin 2
mRNA levels compared to vehicle treated cells (76 ± 3%, and 77 ± 3% increase,
respectively) (Fig. 4. A). ConA pretreatment significantly (p<0.01) blocked the effect of
CP55940 and GP1a on β-Arrestin 2 mRNA levels compared to controls (Fig. 4. A). The
two-way ANOVA showed a main effect of ConA (F1,107 =0.93, p<0.0001), cannabinoid
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agonists (F2,35 =0.31, p<0.0001), and a main interaction between these two factors (F2,32
=0.276, p<0.0001) on β-Arrestin 2 mRNA levels.
Interestingly, a recent study shows that some cannabinoid agonists are more efficacious CB2
receptor internalizers than other cannabinoid agonists [41]. Indeed, CP55940 and GP1a
would be efficacious CB2 receptor internalizers while aminoakyindoles, such as JWH-073,
were classified as poor CB2 receptor internalizers [41]. We then tested the effect of either
vehicle, JWH-073, GP1a, or CP55940 on β-Arrestin 2 mRNA levels in neuronal cells. We
found that either GP1a or CP55940 treatment produced significant (p<0.01) increases in the
β-Arrestin 2 mRNA levels while JWH-073 treatment did not significantly alter β-Arrestin 2
mRNA levels (Fig 4B). These results obtained seems to indicate that CB2 internalization of
CB2 receptors is a critical step in the upregulation of β-Arrestin 2 mRNA.
3.9 Agonists of CB2 receptors would mediate the upregulation of β-Arrestin 2 via ERK1/2
in CLU213 cells
We also aimed to investigate the mechanism by which CB2 receptor induces the
upregulation of β-Arrestin 2. CB2 receptors are positively coupled to the ERK1/2 signaling
pathway [16]. We used PD198306, a selective ERK1/2 inhibitor [42], to study the effect of
GP1a-induced ERK1/2 activation on β-Arrestin 2 upregulation. GP1a exhibits higher
selectivity for CB2 receptors than JWH-133 therefore we utilized GP1a in these
experiments (approx. 9,000- and 200-fold selectivity between CB2/CB1 receptors for GP1a
and JWH-133, respectively) [32;33]. Here, cells were pretreated with either vehicle or
PD198306 (200nM) for 20 min and then treated with either vehicle or GP1a (1nM) for 24h.
GP1a treatment significantly (p<0.01) increased β-Arrestin 2 mRNA levels compared to
vehicle treated controls (104 ± 10% increase, Fig 5A). This GP1a-induced upregulation of
β-Arrestin 2 was prevented (p<0.01) in cells pretreated with PD198306 (Fig. 5.A). The two-
way ANOVA for β-Arrestin 2 mRNA showed significant main effects of PD198306
pretreatment (F1,30.2 =0.54, p<0.0006) and GP1a treatment (F1,48.8 =0.87, p<0.0001). There
was a significant interaction between PD198306 and GP1a treatment (F1,41.6 =0.74,
p<0.0002).
We then used cells stably transfected with either β-Arrestin 2 or control shRNA lentiviral
particles to study the contribution of β-Arrestin 2 to the cannabinoid-induced increases in
nuclear-associated pERK. ERK1/2 is activated through phosphorylation and once
phosphorylated this protein can translocate from the cytoplasm to the nucleus [43]. Cells
transfected with either control or β-Arrestin 2 shRNA lentiviral particles were treated with
vehicle or CP55940 (1nM) for 15 min. We found that treatment with CP55940 significantly
(p<0.01) increased nuclear-associated pERK levels in control shRNA treated cells compared
to vehicle treated controls (Fig. 5.B). The CP55940 induced increases in nuclear-associated
pERK levels were significantly (p<0.01) reduced in cells stably transfected with β-Arrestin
2 shRNA lentiviral particles (Fig. 5.B). Additionally, CP55940 treatment significantly
(p<0.01) increased nuclear-associated pERK levels in β-Arrestin 2 shRNA lentiviral treated
cells compared to vehicle treated controls. The two-way ANOVA for nuclear-associated
pERK showed significant main effects of transfection (F1,429084 =39.41, p<0.0001) and
CP55940 treatment (F1,444167 = 40.79, p<0.0001). There was a significant interaction
between transfection and CP55940 treatment (F1,191213 =175.7, p<0.0001).
Cells transfected with either control or β-Arrestin 2 shRNA lentiviral particles were also
treated with either vehicle or GP1a for 15 minutes. We found that treatment with GP1a
significantly (p<0.01) increased nuclear-associated pERK levels in control shRNA treated
cells compared to vehicle treated controls (Fig 5C). β-Arrestin 2 shRNA lentivirus
transfection significantly (p<0.01) reduced GP1a-induced increases in pERK levels (Fig
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5C). Treatment with GP1a significantly (p<0.01) increased nuclear-associated pERK levels
in β-Arrestin 2 shRNA treated cells compared to vehicle treated controls. The two-way
ANOVA for nuclear-associated pERK showed significant main effects of transfection
(F1,131794 =18.3, p<0.0001) and GP1a treatment (F1,142369 = 19.8, p<0.0008). There was a
significant interaction between transfection and GP1a treatment (F1,252455 =350.5,
p<0.0001).
3.10 Transcription factor AP-1, but not CREB, would be involved in GP1a induced
upregulation of β-Arrestin 2 in CLU213 cells
Here we wanted to identify possible transcription factor(s) that would contribute to GP1a-
induced increases in β-Arrestin 2 mRNA. The results presented above seem to indicate that
ERK1/2 activation is a mechanism involved in the CB2 upregulation of β-Arrestin 2 mRNA.
In the nucleus, phosphorylated ERK (pERK) can activate several transcription factors
including CREB, c-Fos, SP-1, and EGR-1 [43]. The transcription factors CREB and AP-1
have consensus sequences within the promoter region of the rat β-Arrestin 2 gene [44].
Therefore, we decided to test the effects of inhibitors of these transcription factors on the
GP1a-induced upregulation of β-Arrestin 2 mRNA.
CREB is a transcription factor which binds the cAMP response element (CRE) to regulate
the transcription of genes [45]. c-Fos belongs to the immediate early gene family of
transcription factors and this family can dimerize with c-jun to form the AP-1 transcription
factors to upregulate transcription of various genes [46]. In our first experiment, we studied
the effect of CREB inhibitor pretreatment on the GP1a-induced upregulation of β-Arrestin 2.
Here, CLU213 cells were treated with either vehicle or Naphthol AS-E phosphate (10μM)
for 20 min and then treated with vehicle or GP1a (1nM). Naphthol AS-E phosphate blocks
cAMP-induction of CREB-dependent gene transcription (Ki=10μM) [39]. We found that
Naphthol AS-E phosphate did not inhibit or significantly decrease GP1a-induced increases
in β-Arrestin 2 mRNA (Fig. 6.A). No significant (p>0.05) effect of Naphthol AS-E
phosphate was found on basal β-Arrestin 2 mRNA levels either. The two-way ANOVA for
β-Arrestin 2 mRNA showed no significant main effect of Naphthol AS-E phosphate
pretreatment (F1,0.004 =0.038, p>0.0557) and a significant main effect of GP1a treatment
(F1,1.29 =116.6, p<0.0001). There was no significant interaction between Naphthol AS-E
pretreatment and GP1a treatment (F1,0.007 =0.683, p>0.683) on.
We also studied the effect of AP-1 inhibition on GP1a-induced increases in β-Arrestin 2
mRNA. Here neuronal cells were treated with either vehicle or SR11302 (1μM) for 20 min
then vehicle or GP1a (1nM) was added to the incubation media. SR11302 is a retinoid
which transrepresses AP-1 without transactivating the retinoic acid response element (Emax=
1 μM) [47]. As expected, GP1a induced a significant (p<0.01) increase in β-Arrestin 2
mRNA levels (Fig. 6.B). SR11302 pretreatment significantly reduced (approximately 49%
decrease, p<0.01) the GP1a-induced upregulation of the β-Arrestin 2 mRNA (Fig. 6B). No
significant (p>0.05) effect of SR11302 was found in basal β-Arrestin 2 mRNA levels. The
two-way ANOVA for β-Arrestin 2 mRNA did not show a significant main effect of
SR11302 pretreatment (F1,0.12 =4.46, p>0.0676) but did show a significant effect of GP1a
treatment (F1,0.88 p<0.0005). There was a significant interaction between SR11302
pretreatment and GP1a treatment (F 1,0.24 =8.71, p<0.0184). These results suggest that
AP-1, but not CREB, would mediate at least in part the GP1a-induced upregulation of β-
Arrestin 2.
4. Discussion
β-Arrestin 1 and 2 were initially found to hinder G protein coupling of agonist-activated G-
protein coupled receptors (GPCR) resulting in GPCR desensitization; however, recent
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evidence shows that β-Arrestins can also function to activate signaling cascades independent
of G protein activation and can function in receptor internalization [17–19]. The classical
paradigm of agonist-induced GPCR mediated signal transduction involves agonist-induced
dissociation of the G proteins from the GPCR and subsequent G protein regulation of
secondary messengers [48;49]. It was found that G protein-coupled receptor kinases (GRKs)
could terminate this agonist-induced signaling response through phosphorylation of the
receptor [17]. GRK mediated phosphorylation of the receptor triggers the binding of β-
Arrestins to the receptor preventing further G-protein mediated activation of the secondary
messengers [17]. However, recent evidence has identified that β-Arrestins can recruit
proteins such as ERK1/2 to the GPCR to form scaffolding complexes that can regulate the
activation of signaling cascades [48;49].
Interestingly, previous reports showed that chronic exposure to THC (tetrahydrocannabinol,
CB1/CB2 receptor agonist) upregulates β-Arrestin1 in striatum and β-Arrestin 2 in
cerebellum and hippocampus [50] but did not upregulate total ERK1/2 levels in
hippocampus [51]. Currently, the consequences of this upregulation of β-Arrestins on
scaffolding mediated regulation of signaling cascades are unknown. Other research has
identified that β-Arrestins can bind proteins involved in receptor internalization and can
bring activated receptors along with scaffolding proteins to clathrin-coated pits for
endocytosis [48;49]. After internalization of the GPCR, evidence indicates that the
scaffolding complex can continue to regulate signaling cascades [19].
Our results indicate that exposure to CP55940, a CB1/CB2 receptor agonist, increases the
interaction between β-Arrestin 2 and ERK1/2 in rat PFCx (Fig. 1.A). Co-
immunoprecipitation has been successfully used by some groups to demonstrate an
interaction between β-Arrestin 2 and its scaffolding proteins [52–54]. Interestingly, this
enhanced β-Arrestin 2 and ERK1/2 interaction in the PFCx of CP55940 treated rats was
associated with enhanced CP55940-induced ERK1/2 activation (Fig. 1.B). In previous work
we have found cannabinoid-induced ERK1/2 activation is needed for the upregulation of 5-
HT2A receptors hence cannabinoid regulation of the β-Arrestin and ERK1/2 interaction
could play an essential role in the upregulation of 5-HT2A receptors through regulation of
ERK1/2 signaling. Changes in β-Arrestin 2 and/or ERK1/2 expression could contribute to
this cannabinoid agonist-induced enhanced β-Arrestin 2 and ERK1/2 interaction.
Interestingly, we found that CP55940 treatment increased β-Arrestin 2 protein levels while
ERK1/2 protein levels were not significantly altered in the PFCx of rats (Fig. 1.C and 1D).
Therefore changes in β-Arrestin 2 protein expression but not ERK1/2 protein expression
may be contributing to this enhanced β-Arrestin 2 and ERK1/2 interaction in the PFCx.
Moreover, we found increased β-Arrestin 2 mRNA in PFCx of CP55940 treated rats
compared to controls (Fig. 1.E) suggesting that increases in β-Arrestin 2 expression most
likely occurs through cannabinoid-mediated enhanced transcription of the β-Arrestin 2 gene.
Finally, treatment with β-Arrestin 2 lentiviral particles prevented the cannabinoid-induced
upregulation of 5-HT2A receptors (Fig. 1.F). This evidence indicates that β-Arrestin 2 is
necessary for the cannabinoid-induced upregulation of 5-HT2A receptors and suggests that
regulation of 5-HT2A receptor expression may be mediated by changes in β-Arrestin 2
expression and formation of the scaffolding complex.
We used a neuronal cell line, selective CB1 and CB2 receptor agonists or antagonists, and
CB1 and CB2 shRNA lentiviral particles to determine the contribution of CB1 and CB2
receptors to the regulation of β-Arrestin 2 mRNA levels. In our neuronal cell line which
expresses CB1 and CB2 receptors, we found that treatment with the non-selective CB1/CB2
agonist CP55940 and treatment with the selective CB2 receptors agonists, JWH-133 and
GP1a, increased β-Arrestin 2 mRNA and protein levels (Fig. 2.A and 2B). This
cannabinoid–induced upregulation of β-Arrestin 2 was not mimicked by a selective CB1
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agonist (ACEA) (Fig. 2.A) suggesting that CB2 receptors may be mediating this response.
Additionally, we found that a selective CB2 receptor antagonist JTE-907, but not a selective
CB1 receptor antagonist PF-514273, prevented the CP55940-induced increases in β-
Arrestin 2 mRNA levels (Fig. 2.C). Moreover, treatment with CB2 shRNA lentiviral
particles, but not CB1 shRNA lentiviral particles, prevented the CP55940, JWH-133, and
GP1a-induced increases β-Arrestin 2 mRNA levels (Fig. 3.B and 3C). This evidence
indicates the CB2 receptors are required for the cannabinoid-induced upregulation of β-
Arrestin 2.
Recent evidence indicates that CB2 receptor ligands can distinctly regulate the signal
transduction mechanisms associated with the CB2 receptors, a phenomenon known as
functional selectivity [19;41;55]. Atwood et al. have identified different classes of
cannabinoid receptor agonists which differ in their ability induce internalization of CB2
receptors [41]. They generalize that bicyclic cannabinoid such as CP55940 would be
efficacious CB2 receptor internalizers while aminoakylindoles would be poor CB2 receptor
internalizers. We found that CP55940, but not JWH-073, induced β-Arrestin 2 upregulation
(Fig. 4.B), suggesting that upregulation of β-Arrestin 2 is dependent on the ability of the
agonists to promote internalization of CB2 receptors. To further explore this possibility, we
pretreated cells with ConA which is commonly used to prevent clathrin mediated
endocytosis of GPCRs [38;56] and then treated cells with CP55940 or GP1a. Interestingly,
ConA pretreatment prevented the CP55940- and GP1a-induced increases in β-Arrestin 2
mRNA levels in cultured cells (Fig. 4.A). This evidence further suggests that internalization
of the CB2 receptor is needed for the cannabinoid-induced upregulation of β-Arrestin 2.
We tested the effect of PD198306, a potent ERK1/2 inhibitor, on the CB2-induced
upregulation of β-Arrestin 2 [12;42]. Previous studies have identified that 200 nM of
PD198306 can prevent ERK1/2 activation in breast cancer cells [42]. We found the
PD198306 pretreatment prevented the selective CB2 receptor agonist induced increases in
β-Arrestin 2 mRNA levels (Fig. 5.A). This evidence suggests that CB2 receptors can induce
the upregulation of β-Arrestin 2 through a mechanism that involves ERK activation.
Currently, the mechanism by which CB2 receptors mediate the activation of ERK1/2 has not
been well defined. It is known that β-Arrestins can form scaffolding complexes with
ERK1/2 which can mediate its activation [19]. We found that β-Arrestin 2 shRNA lentiviral
particle treatment significantly reduced the CP55940 and GP1a-induced increases in
nuclear-associated pERK compared to vehicle treated controls (Fig. 5.B and 5C). Yet
treatment with CP55940 and GP1a significantly increased nuclear pERK levels in β-
Arrestin 2 shRNA lentivirus treated cells compared vehicle treated controls. This evidence
suggests that CB2 receptors can mediate ERK1/2 activation, at least in part, through β-
Arrestin 2. Here the CP55940 and GP1a induced increased in pERK levels in β-Arrestin 2
shRNA lentivirus treated cells could be attributed to: (1) residual β-Arrestin 2 left over after
β-Arrestin 2 shRNA lentivirus treatment (approximately 15%) and/or (2) β-Arrestin 1
mediated activation of ERK1/2 signaling. It has been found that β-Arrestins can functionally
substitute for the other isoform to some degree [49]. However, internalization of GPCRs is
typically mediated primarily by one isoform of β-Arrestin [49].
Our results suggest that inhibition of AP-1, but not CREB, significantly decreased the GP1a-
induced upregulation of 5-HT2A receptors (Fig. 6.A and 6B). The partial inhibition of the
GP1a-induced increases in β-Arrestin 2 mRNA levels by SR11302 suggest that other
transcription factors yet to be identified could also contribute to this upregulation.
Chronic cannabinoid receptor agonist exposure have been associated with several
neuropsychiatric disorders such as schizophrenia, anxiety, and depression [6–8;57].
Interestingly, dysregulation of 5-HT2A and D2 receptor signaling has been associated with
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schizophrenia, stress response, anxiety, and depression [58–61]. While a causal link between
chronic cannabinoid agonist exposure and these neuropsychiatric disorders has not been
found, it has been suggested that long-term cannabinoid agonist exposure may precipitate
these neuropsychiatric disorders [6–8;57]. Interestingly, repeated exposure to a cannabinoid
agonist, CP55940, leads to increased anxiety and long-term memory impairments that
irrespective of the age at which drug exposure occurs [62]. More importantly, recent
evidence indicates that repeated exposure to a selective CB2 receptor agonist, JWH-133,
induces anxiety-like behaviors in rodents that are blocked by a selective CB2 receptor
antagonist [63]. This evidence highlights the need to identify the mechanisms by which
sustained cannabinoid exposure induces and/or contributes to neuropsychiatric disorders.
Noteworthy, in our previous reports we found that CB2 receptor–mediated upregulation of
5-HT2A receptors [10] could contribute to the cannabinoid-induced enhanced interaction
between 5-HT2A and D2 receptors in PFCx [9]. Here, we aimed to identify the molecular
mechanisms contributing to this upregulation of 5-HT2A receptors and specifically we
focused on the role of β-Arrestin 2 in this phenomenon. In summary, our results suggest that
sustained activation of CB2 receptors would enhance β-Arrestin 2 expression possibly
contributing to its increased interaction with ERK1/2 thereby driving the upregulation of 5-
HT2A receptors. The CB2 receptor-mediated upregulation of β-Arrestin 2 would be
mediated, at least in part, by an ERK1/2-dependent activation of AP-1.
5. Conclusion
Emerging studies are identifying that selective CB2 receptor agonists such as JWH-133 have
wide therapeutic application in the treatment of conditions such as stroke, neurogenerative
diseases, and neuropathic pain [1–4]. However, the mechanism that we are currently
defining could represent a potential adverse effect of the long-term use of selective CB2
receptor agonists such as GP1a and JWH-133. Repeated exposure to these agonists, that are
efficacious CB2 receptor internalizers, could be associated with potential adverse effects as
mentioned above. However, our evidence suggest that CB2 receptor agonists such as
JWH-073, that are categorized as poor CB2 receptor internalizers, could represent an
alternative therapeutic approach that may have minimal effect on serotonergic
neurotransmission in brain thereby reducing the adverse effects that may be associated with
enhanced 5-HT2A receptor function.
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Figure 1. CP55940-induced enhanced co-immunoprecipitation of β-Arrestin 2 and ERK1/2 and
increased β-Arrestin 2 protein expression in rat PFCx
(A) Enhanced immunoprecipitation of the ERK1/2 (Lane 4) compared to vehicle-treated
controls (Lane 3). Negative controls (Lanes 5 and 6) received the same concentration of β-
Arrestin 2 antibody except that the coupling resin was replaced with control agarose resin
that is not amine reactive. All columns were incubated with prefrontal cortex lysate (300 μg)
from vehicle (Lanes 3 and 5 ) or CP55940 (Lanes 4 and 6) treated rats. Prefrontal cortex
lysate (30 μg of protein) was used as an input control (Lane 1 and 2). (B) Increased pERK
protein levels in CP55940 treated rats compared to vehicle treated rats. **p<0.01,
significant effect of CP55940 treatment compared to vehicle-treated controls. (C) Increased
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membrane associated β-Arrestin 2 protein levels in PFCx of CP55940 treated rats. **p<0.01
significant effect of CP55940 treatment compared to vehicle-treated controls. (D) CP55940
treatment does not affect total ERK1/2 expression in the PFCx. (E) Increased β-Arrestin 2
mRNA levels in PFCx of CP55940 treated rats. *p<0.01 significant effect of CP55940
treatment compared to vehicle treated controls. (F) β-Arr2 shRNA lentivurs transfection
prevents GP1a-induced increases in 5-HT2A receptor mRNA. **p<0.01, significant effect of
GP1a treatment on 5-HT receptor mRNA levels in control shRNA tranfected cells
compared 2A to vehicle-treated controls. ##p<0.01, significant effect of β-Arr2 shRNA
transfection on the GP1a-induced upregulation of 5-HT2A receptors. Representative Western
blots are shown in this figure and IOD was calculated as described in Experimental
Procedures. The data represent mean ± SEM (n=6–8).
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Figure 2. Selective CB2 receptor agonists, GP1a and JWH-133, upregulate β-Arrestin 2 and
selective CB2 receptor antagonist, JTE-907, prevent cannabinoid-induced upregulation of β-
Arrestin 2 in CLU213 cells
(A) Increased β-Arrestin 2 mRNA levels in CP55940, JWH-133, and GP1a treated cells.
ACEA treatment did not significantly alter β-Arrestin 2 mRNA levels. **p<0.01 significant
effect of CP55940, JWH-133, or GP1a treatment compared to vehicle-treated controls. (B)
Increased β-Arrestin 2 protein levels in CP55940, JWH-133, and GP1a treated cells.
**p<0.01 significant effect of CP55940, JWH-133, or GP1a compared to vehicle-treated
controls (C) Selective CB2 receptor antagonists pretreatment JTE-907 prevents CP55940-
induced increases in β-Arrestin 2 mRNA. **p<0.01, significant effect of CP55940 treatment
on β-Arrestin 2 mRNA levels compared to vehicle-treated controls. ##p<0.01, significant
effect of JTE-907 pretreatment on the CP55940-induced upregulation of β-Arrestin 2
mRNA levels (D) JTE-907 prevents GP1a-induced increases in β-Arrestin 2 mRNA levels.
**p<0.01, significant effect of GP1a treatment on β-Arrestin 2 mRNA levels compared to
vehicle treated controls. ##p<0.01, significant effect of pretreatment on GP1a-induced
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upregulation of β-Arrestin 2 mRNA levels. Representative Western blots are shown in this
figure and IOD was calculated as described in Experimental Procedures. The data represent
mean ± SEM (n=3).
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Figure 3. CB2 receptors are necessary for CP55940, JWH-133, and GP1a-induced upregulation
of β-Arrestin 2 in CLU213 cells
(A) Reduced CB2 or CB1 mRNA levels in cells treated with CB2 or CB1 shRNA lentiviral
particles, respectively. **p<0.01 significant effect of CB2 or CB1 shRNA compared to
control shRNA treated cells. (B) CB2 shRNA lentivitrarus transfection prevents CP55940,
JWH-133 and GP1a-induced increases in β-Arrestin 2 mRNA. **p<0.01, significant effect
of CP55940, JWH-133, and GP1a treatment on β-Arrestin 2 mRNA levels in control
shRNA lentivirus tranfected cells compared to vehicle-treated controls. ##p<0.01,
significant effect of CB2 shRNA lentivirus transfection on the CP55940, JWH-133, and
GP1a-induced upregulation of β-Arrestin 2. (C) CB1 shRNA lentivirus transfection does not
prevent CP55940, JWH-133 or GP1a-induced increases β-Arrestin 2. **p<0.01, significant
effect of CP55940, JWH-133 or GP1a treatment on β-Arrestin 2 mRNA levels in control or
CB1 shRNA lentvirus treated cells compared to vehicle-treated controls. The data represent
mean ± SEM (n=3).
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Figure 4. CP55940 and GP1a may upregulate β-Arrestin 2 via CB2 receptor internalization in
CLU213 cells
(A) Increased β-Arrestin 2 mRNA levels in cells treated with either CP55940 or GP1a.
significant effect of CP55940 and GP1a treatment on β-Arrestin 2 mRNA levels compared
to vehicle-treated controls. ##p<0.01, significant effect of ConA pretreatment on the
CP55940 and GP1a-induced upregulation of β-Arrestin 2. The data represent mean ± SEM
(n=3).
Franklin et al. Page 24













Figure 5. GP1a, a selective CB2 receptor agonist, upregulate β-Arrestin 2 via ERK1/2 signaling
CLU213 cells
(A) PD198306, potent ERK1/2 inhibitor, pretreatment prevents GP1a-induced increases β-
Arrestin 2 mRNA levels. **p<0.01, significant effect of GP1a treatment compared to
vehicle-treated controls. ##p<0.01, significant effect of PD198306 pretreatment on GP1a-
induced increases β-Arrestin 2 mRNA levels compared to vehicle-treated controls (B) β-
Arrestin 2 shRNA lentivirus treatment significantly reduced CP55940 induced increased in
nuclear-associated pERK levels. **p<0.01, significant effect of CP55940 treatment on
nuclear-associated pERK levels in control or β-Arrestin 2 shRNA treated cells compared to
vehicle-treated. ##p<0.01, significant effect of β-Arrestin 2 shRNA treatment in CP55940
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treated cells compared to control shRNA transfect/CP55940 treated cells. (C) β-Arrestin
shRNA lentivirus treatment significantly reduced GP1a-induced increases in nuclear-
associated pERK levels. **p<0.01, significant effect of GP1a treatment on nuclear-
associated pERK levels in control or β-Arrestin 2 shRNA treated cells compared to vehicle-
treated controls. ##p<0.01, significant effect of β-Arrestin 2 shRNA treatment in CP55940
treated cells compared to control shRNA transfected/CP55940 treated cells. The data
represent mean ± SEM (n=3).
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Figure 6. CB2 receptor-induced upregulation of β-Arrestin 2 involves AP-1, but not CREB,
activation
(A) Inhibition of CREB activation did not prevent or significantly reduce GP1a-induced
increases in β-Arrestin 2 mRNA. **p<0.01, significant effect of GP1a and CREB/GP1a
treatment on β-Arrestin 2 mRNA levels compared to vehicle-treated controls. (B) CB2
receptor-mediated upregulation of β-Arrestin 2 involves AP-1 transcription factor activity.
**p<0.01, significant effect of GP1a treatment compared to vehicle-treated controls.
##p<0.01, significant effect of AP-1 transcription factor inhibitor pretreatment on GP1a-
induced increases in β-Arrestin 2 mRNA. The data represent mean ± SEM (n=3).
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